Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:MMYT News 9 January 2026 - 23 January 2026

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings shares slipped 0.25% to $5,150.90 Thursday, bucking gains in broader U.S. indexes and sector peers like Expedia. Trading volume reached about 220,000 shares. The company set February 18 for its fourth-quarter and full-year results release. Navan announced an expanded API integration with Booking.com to offer more lodging options for business travelers.
23 January 2026
······
MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip stock slides 4.5% in U.S. trade as investors turn to Jan. 22 earnings

MakeMyTrip shares fell 4.5% to $78.78 in Friday afternoon trading, underperforming U.S.-listed travel peers. The stock hit a session high of $83.42 before sliding, with no new company updates ahead of its expected Jan. 22 earnings. Trading volume reached about 577,000 shares by mid-session. The drop puts MakeMyTrip near its lowest levels since early January.
9 January 2026
··

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop